• Amit Bar-Or.
• Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4; Experimental Therapeutics Program, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4; Clinical Research Unit, Montreal Neurological Institute, McGill University, 3801 University Street, # 111, Montreal, Quebec, Canada, H3A 2B4. Electronic address: amit.bar-or@mcgill.ca.
• Exp. Neurol. 2014 Dec 1;262 Pt A:57-65.

AbstractTeriflunomide (Aubagio®) is a once-daily oral immunomodulatory disease modifying therapy (DMT) presently approved in several regions, including Europe, North America, Latin America and Australia, for the treatment of relapsing forms of multiple sclerosis (RMS; RRMS). The therapeutic mode of action of teriflunomide in MS continues to be investigated. This review summarizes the main efficacy and safety results of the clinical trial program leading to teriflunomide's approval, highlights a number of practical clinical considerations, and overviews its presumed therapeutic mode of action (MOA) based on pharmacokinetic and pharmacodynamic observations and the growing body of teriflunomide-related in vitro, pre-clinical (animal model), and in vivo human studies.Copyright © 2014 Elsevier Inc. All rights reserved.

17 keywords...

hide…